Incanthera PLC - Further re: Director's Dealing
Announcement provided by
Incanthera plc · INC20/07/2023 07:00
20 July 2023
Incanthera plc
("Incanthera" or the "Company")
Further re: Director's Dealing
On 13 March 2023, the Company announced that Dr. Simon Ward (CEO of the Company) invested approximately
The Company advises that Dr. Ward has, as a consequence, changed his pension provider and sought to subscribe for the Investment Shares. However, due to ongoing administrative restrictions on the quantum of the investment Dr. Ward is able to make from his SIPP, he remains unable to invest the intended amount. He has, therefore, invested from his SIPP,
The subscription for the 360,000 Investment Shares and the provision of the
As a result of the Subscription funds being received, application for admission of 360,000 new ordinary shares ("Subscription Shares") to the AQSE Growth market ("Admission") has been made and is expected to occur on or around 08:00 a.m. on 25 July 2023. The Subscription Shares will rank pari passu with the existing ordinary shares.
Following Admission of the Subscription Shares, the Company's enlarged issued share capital will comprise 77,824,166 ordinary shares of
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
For further enquiries:
Incanthera plc:
Tim McCarthy, Chairman tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP +44 (0) 20 7213 0880
Jo Turner/Ludovico Lazzaretti
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney +44 (0) 20 3650 3650
Notes to Editors
Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
1 |
Details of the persons discharging managerial responsibilities / person closely associated
|
|||||
a) |
Name
|
Simon Ward |
||||
2 |
Reason for the notification
|
|||||
a) |
Position/Status
|
CEO |
||||
b) |
Initial notification/ Amendment
|
Amendment |
||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
a) |
Name
|
Incanthera plc |
||||
b) |
LEI
|
2138002HEV4UFBOEXQ97 |
||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares
GB00BGL7YW15
|
||||
b) |
Nature of the transaction |
Acquisition of ordinary shares |
||||
c) |
Price(s) and volume(s)
|
|
||||
d) |
Aggregated information
- Aggregated volume
- Price
|
360,000
|
||||
e) |
Date of transaction
|
19 July 2023 |
||||
f) |
Place of transaction
|
AQSE Stock Exchange, London |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.